The FDA slapped an Aquebogue, New York drug manufacturer with a warning letter over serious data integrity lapses and violations related to environmental and personnel monitoring.

The FDA hit a Paterson, New Jersey contract testing laboratory with a warning letter for active pharmaceutical ingredient (API) testing violations.

The FDA hit California drugmaker Blaine Labs with a warning letter for serious violations at its Santa Fe Springs facility, including the failure to investigate out-of-specification (OOS) test results.